CABA Key Statistics, Chart & Performance
The current stock price of CABA is 2.15 USD. In the past month the price decreased by -11.52%. In the past year, price decreased by -10.42%.
CABA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About CABA
Company Profile
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Company Info
CABALETTA BIO INC
2929 Arch Street, Suite 600
PHILADELPHIA PENNSYLVANIA 19104 US
CEO: Steven Nichtberger
Employees: 148
Phone: 12677593100
CABALETTA BIO INC / CABA FAQ
What does CABALETTA BIO INC do?
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Can you provide the latest stock price for CABALETTA BIO INC?
The current stock price of CABA is 2.15 USD. The price decreased by -5.7% in the last trading session.
Does CABALETTA BIO INC pay dividends?
CABA does not pay a dividend.
How is the ChartMill rating for CABALETTA BIO INC?
CABA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the market capitalization of CABA stock?
CABALETTA BIO INC (CABA) has a market capitalization of 206.98M USD. This makes CABA a Micro Cap stock.
Who owns CABALETTA BIO INC?
You can find the ownership structure of CABALETTA BIO INC (CABA) on the Ownership tab.
Can you provide the short interest for CABA stock?
The outstanding short interest for CABALETTA BIO INC (CABA) is 20% of its float.
CABA Technical Analysis
CABA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CABA. CABA has a bad profitability rating. Also its financial health evaluation is rather negative.
CABA Financial Highlights
Over the last trailing twelve months CABA reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS decreased by -17.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.54% | ||
| ROE | -113.66% | ||
| Debt/Equity | 0.03 |
CABA Forecast & Estimates
16 analysts have analysed CABA and the average price target is 14.41 USD. This implies a price increase of 570.12% is expected in the next year compared to the current price of 2.15.